EUCTR2015-000943-17-NL进行中（未招募）1 期
Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial. - Tight control dose decrease of biologics for psoriasis
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Radboudumc
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Sustained low disease activity (PASI<5 for at least 6 months, DLQI <5 at inclusion) on the regular dose as advised by the label.
- •Established diagnosis of plaque psoriasis.
- •Receiving treatment with adalimumab, etanercept, or ustekinumab for at least 6 months.
- •Age =18 years.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •Psoriasis itself is not the main reason for biologic prescription (e.g. when a patient has RA and psoriasis, and RA is the main reason for the biologic).
- •Concomitant use of immunosupressants other than methotrexate or acitretin for psoriasis.
- •Severe comorbidities with short life-expectancy (e.g. metastasized tumour).
- •Presumed inability to follow the study protocol.
研究者
相似试验
已完成
4 期
Tight control dose reductions of biologics in psoriasis patients with low disease activity: a randomized pragmatic trial.NL-OMON42814Academisch Medisch Centrum120
尚未招募
不适用
Dose decrease of biologics in psoriasis patients with low disease activity.psoriasis, biologics, tnf-alfa remmers, etanercept, adalimumab, ustekinumab, dosis reductie, dose reduction, dose decreaseNL-OMON24722Radboudumc, Nijmegen, The Netherlands120
进行中（未招募）
1 期
Dose reduction of IL17 and IL23 inhibitors for psoriasispsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10037155Term: Psoriasis and similar disordersSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersMedDRA version: 20.0Level: LLTClassification code 10050576Term: Psoriasis vulgarisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2019-004230-42-NLRadboudumc244
尚未招募
不适用
Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio studyNL-OMON29024ZonMw, KCE244
招募中
4 期
Dose reduction of the new generation biologics (IL17 and IL23 inhibitors) in psoriasis: A pragmatic, multicentre, randomized, controlled, non-inferiority study - BeNeBio studyNL-OMON52624Academisch Medisch Centrum142